Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DCC-3084 |
Synonyms | |
Therapy Description |
DCC-3084 is a switch control inhibitor targeting class 1, 2, and 3 BRAF mutations, fusions, and BRAF/CRAF heterodimers, which potentially inhibits Mapk signaling, proliferation, and tumor growth (Cancer Res (2023) 83 (7_Supplement): 4045). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCC-3084 | DCC 3084|DCC3084 | BRAF Inhibitor 25 CRAF Inhibitor 12 | DCC-3084 is a switch control inhibitor targeting class 1, 2, and 3 BRAF mutations, fusions, and BRAF/CRAF heterodimers, which potentially inhibits Mapk signaling, proliferation, and tumor growth (Cancer Res (2023) 83 (7_Supplement): 4045). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF class 2 | Advanced Solid Tumor | predicted - sensitive | DCC-3084 | Preclinical - Cell culture | Actionable | In a preclinical study, DCC-3084 inhibited downstream signaling and proliferation in cells expressing a BRAF class 2 mutation in culture (Cancer Res (2023) 83 (7_Supplement): 4045). | detail... |
BRAF fusion | Advanced Solid Tumor | predicted - sensitive | DCC-3084 | Preclinical - Cell culture | Actionable | In a preclinical study, DCC-3084 inhibited downstream signaling and proliferation in cells expressing a BRAF fusion in culture (Cancer Res (2023) 83 (7_Supplement): 4045). | detail... |
BRAF class 3 | Advanced Solid Tumor | predicted - sensitive | DCC-3084 | Preclinical - Cell culture | Actionable | In a preclinical study, DCC-3084 inhibited downstream signaling and proliferation in cells expressing a BRAF class 3 mutation in culture (Cancer Res (2023) 83 (7_Supplement): 4045). | detail... |
BRAF class 1 | Advanced Solid Tumor | predicted - sensitive | DCC-3084 | Preclinical - Cell culture | Actionable | In a preclinical study, DCC-3084 inhibited downstream signaling and proliferation in cells expressing a BRAF class 1 mutation in culture (Cancer Res (2023) 83 (7_Supplement): 4045). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06287463 | Phase Ib/II | DCC-3084 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | Recruiting | USA | 0 |